Cargando…

Obesity paradox in cardiovascular disease: where do we stand?

Obesity is associated with an increased risk of developing cardiovascular disease (CVD), particularly heart failure (HF) and coronary heart disease (CHD). The mechanisms through which obesity increases CVD risk involve changes in body composition that can affect hemodynamics and alters heart structu...

Descripción completa

Detalles Bibliográficos
Autores principales: Carbone, Salvatore, Canada, Justin M, Billingsley, Hayley E, Siddiqui, Mohammad S, Elagizi, Andrew, Lavie, Carl J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503652/
https://www.ncbi.nlm.nih.gov/pubmed/31118651
http://dx.doi.org/10.2147/VHRM.S168946
_version_ 1783416446438604800
author Carbone, Salvatore
Canada, Justin M
Billingsley, Hayley E
Siddiqui, Mohammad S
Elagizi, Andrew
Lavie, Carl J
author_facet Carbone, Salvatore
Canada, Justin M
Billingsley, Hayley E
Siddiqui, Mohammad S
Elagizi, Andrew
Lavie, Carl J
author_sort Carbone, Salvatore
collection PubMed
description Obesity is associated with an increased risk of developing cardiovascular disease (CVD), particularly heart failure (HF) and coronary heart disease (CHD). The mechanisms through which obesity increases CVD risk involve changes in body composition that can affect hemodynamics and alters heart structure. Pro-inflammatory cytokines produced by the adipose tissue itself which can induce cardiac dysfunction and can promote the formation of atherosclerotic plaques. When obesity and HF or CHD coexist, individuals with class I obesity present a more favorable prognosis compared to individuals who are normal or underweight. This phenomenon has been termed the “obesity paradox.” Obesity is defined as an excess fat mass (FM), but individuals with obesity typically also present with an increased amount of lean mass (LM). The increase in LM may explain part of the obesity paradox as it is associated with improved cardiorespiratory fitness (CRF), a major determinant of clinical outcomes in the general population, but particularly in those with CVD, including HF. While increased LM is a stronger prognosticator in HF compared to FM, in patients with CHD excess FM can exert protective effects particularly when not associated with increased systemic inflammation. In the present review, we discuss the mechanisms through which obesity may increase the risk for CVD, and how it may exert protective effects in the setting of established CVD, with a focus on body composition. We also highlight the importance of measuring or estimating CRF, including body composition-adjusted measures of CRF (ie, lean peak oxygen consumption) for an improved risk status stratification in patients with CVD and finally, we discuss the potential non-pharmacologic therapeutics, such as exercise training and dietary interventions, aimed at improving CRF and perhaps clinical outcomes.
format Online
Article
Text
id pubmed-6503652
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65036522019-05-22 Obesity paradox in cardiovascular disease: where do we stand? Carbone, Salvatore Canada, Justin M Billingsley, Hayley E Siddiqui, Mohammad S Elagizi, Andrew Lavie, Carl J Vasc Health Risk Manag Review Obesity is associated with an increased risk of developing cardiovascular disease (CVD), particularly heart failure (HF) and coronary heart disease (CHD). The mechanisms through which obesity increases CVD risk involve changes in body composition that can affect hemodynamics and alters heart structure. Pro-inflammatory cytokines produced by the adipose tissue itself which can induce cardiac dysfunction and can promote the formation of atherosclerotic plaques. When obesity and HF or CHD coexist, individuals with class I obesity present a more favorable prognosis compared to individuals who are normal or underweight. This phenomenon has been termed the “obesity paradox.” Obesity is defined as an excess fat mass (FM), but individuals with obesity typically also present with an increased amount of lean mass (LM). The increase in LM may explain part of the obesity paradox as it is associated with improved cardiorespiratory fitness (CRF), a major determinant of clinical outcomes in the general population, but particularly in those with CVD, including HF. While increased LM is a stronger prognosticator in HF compared to FM, in patients with CHD excess FM can exert protective effects particularly when not associated with increased systemic inflammation. In the present review, we discuss the mechanisms through which obesity may increase the risk for CVD, and how it may exert protective effects in the setting of established CVD, with a focus on body composition. We also highlight the importance of measuring or estimating CRF, including body composition-adjusted measures of CRF (ie, lean peak oxygen consumption) for an improved risk status stratification in patients with CVD and finally, we discuss the potential non-pharmacologic therapeutics, such as exercise training and dietary interventions, aimed at improving CRF and perhaps clinical outcomes. Dove 2019-05-01 /pmc/articles/PMC6503652/ /pubmed/31118651 http://dx.doi.org/10.2147/VHRM.S168946 Text en © 2019 Carbone et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Carbone, Salvatore
Canada, Justin M
Billingsley, Hayley E
Siddiqui, Mohammad S
Elagizi, Andrew
Lavie, Carl J
Obesity paradox in cardiovascular disease: where do we stand?
title Obesity paradox in cardiovascular disease: where do we stand?
title_full Obesity paradox in cardiovascular disease: where do we stand?
title_fullStr Obesity paradox in cardiovascular disease: where do we stand?
title_full_unstemmed Obesity paradox in cardiovascular disease: where do we stand?
title_short Obesity paradox in cardiovascular disease: where do we stand?
title_sort obesity paradox in cardiovascular disease: where do we stand?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503652/
https://www.ncbi.nlm.nih.gov/pubmed/31118651
http://dx.doi.org/10.2147/VHRM.S168946
work_keys_str_mv AT carbonesalvatore obesityparadoxincardiovasculardiseasewheredowestand
AT canadajustinm obesityparadoxincardiovasculardiseasewheredowestand
AT billingsleyhayleye obesityparadoxincardiovasculardiseasewheredowestand
AT siddiquimohammads obesityparadoxincardiovasculardiseasewheredowestand
AT elagiziandrew obesityparadoxincardiovasculardiseasewheredowestand
AT laviecarlj obesityparadoxincardiovasculardiseasewheredowestand